The mitochondria-delivery molecule behind MitoQ slowed heart fat-burning — in lab models

Mitochondria-targeted antioxidants — the class that includes MitoQ — ride into the cell on a molecular delivery vehicle called triphenylphosphonium, or TPP. A new study in Scientific Reports (October 7, 2026) reports that the vehicle itself is not inert: TPP and most of its tested conjugates preferentially shut down long-chain fatty-acid oxidation in mouse heart mitochondria and in a human heart-cell line — the very fuel pathway the heart depends on most.

What is TPP, and where is it used?

TPP is a fat-soluble, positively charged molecule that accumulates inside mitochondria, dragged in by the organelle's own membrane voltage. Drug designers bolt antioxidants and other payloads onto it to concentrate them exactly where oxidative damage happens. It is one of the most widely used targeting strategies in mitochondrial medicine — which is why a paper about its off-target effects lands with weight.

What did the study test?

The researchers treated isolated mouse heart mitochondria with TPP itself, plus the commercial TPP derivatives MitoTEMPO and MitoSOX and a test compound, TPP-aspirin. All except MitoTEMPO — which was relatively inert — preferentially suppressed respiration when mitochondria were burning palmitoyl carnitine (a fatty-acid fuel) versus pyruvate. Direct measurements pinned the block to beta-oxidation inside the inner mitochondrial compartment; the entry enzyme CPT1 was unaffected.

Why is the fatty-acid finding specifically worrying?

The selectivity is the unsettling part: membrane potential and electron-transport-chain activity were largely preserved at the same concentrations that choked fatty-acid burning. Standard toxicity screens that only check those readouts would miss the effect entirely. The same pattern held in AC16 human cardiomyocyte cells, without loss of cell viability — a metabolic handicap, not outright poisoning.

The watchdog read: what this does and doesn't prove

Three caveats keep this in perspective. First, these were isolated mitochondria and a cell line — not a beating heart, and not a person taking a supplement. Second, MitoQ itself was not among the tested compounds, so this is about the delivery chemistry, not a verdict on any product. Third, one TPP conjugate (MitoTEMPO) was largely inert, which suggests the effect is tunable, not inevitable. Still, for a field building therapies on this vehicle, a hidden brake on cardiac fat-burning is exactly the kind of finding that should change how the next compounds are screened.

Where the evidence stands

• Established: TPP is the standard delivery moiety for mitochondria-targeted compounds including MitoQ; the heart depends heavily on fatty-acid oxidation for energy.
• Preliminary: The substrate-selective inhibition was demonstrated in isolated mouse heart mitochondria and the AC16 human cardiomyocyte cell line — not in whole animals or people.
• Absent: Evidence that marketed mitochondria-targeted products impair cardiac metabolism in humans; MitoQ itself was not tested, and one tested compound (MitoTEMPO) was relatively inert.